The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Novel heteroclitic XBP1 peptides evoking antigen-specific cytotoxic T lymphocytes targeting various solid tumors.
Jooeun Bae
Consultant or Advisory Role - OncoPep (U)
Stock Ownership - OncoPep
Ruben Carrasco
No relevant relationships to disclose
John Daley
No relevant relationships to disclose
Glen Dranoff
No relevant relationships to disclose
Kenneth Carl Anderson
Consultant or Advisory Role - OncoPep (U)
Stock Ownership - OncoPep
Nikhil C. Munshi
Consultant or Advisory Role - OncoPep (U)
Stock Ownership - OncoPep